Novel Genetic Products from Ashbya gossypii, Associated with the Structure of the Cell Wall or the C

专利摘要:
The present invention relates to novel polynucleotides from Ashbia Gossip ; Oligonucleotides that hybridize thereto; Expression cassettes and vectors comprising these polynucleotides; Microorganisms transformed therewith; Polypeptides encoded by these polynucleotides; And the use of novel polypeptides and polynucleotides as targets to modulate the properties of cell walls and / or cytoskeleton and in particular to improve vitamin B2 production in microorganisms of the genus Ashvia .
公开号:KR20040029000A
申请号:KR10-2004-7002636
申请日:2002-08-21
公开日:2004-04-03
发明作者:마르빈 카로스；헤닝 알퇴퍼；부르크하르트 크뢰거；요세 엘. 레부엘타도발
申请人:바스프 악티엔게젤샤프트；
IPC主号:

专利说明:

Novel Genetic Products from Ashbya gossypii, Associated with the Structure of the Cell Wall or the Cytoskeleton
[1] The present invention relates to novel polynucleotides from Ashbia Gossip ; Oligonucleotides that hybridize thereto; Expression cassettes and vectors comprising these polynucleotides; Microorganisms transformed therewith; Polypeptides encoded by these polynucleotides; And the use of novel polypeptides and polynucleotides as targets to modulate the properties of the cell wall or cytoskeleton and in particular to improve vitamin B2 production in microorganisms of the genus Ashvia .
[2] Vitamin B2 (riboflavin, lactoflavin) is an alkali- and photo-sensitive vitamin that exhibits yellowish green fluorescence in solution. Vitamin B2 deficiency can lead to ectoderm damage, in particular cataracts, keratitis, corneal angiogenesis, or autonomic and urogenital disorders. Vitamin B2 is, in addition to NAD ⁺ and NADP ⁺ , precursors to molecules FAD and FMN that are biologically important for hydrogen delivery. The molecules FAD and FMN are formed from vitamin B2 by phosphorylation (FMN) and subsequent adenylation (FAD).
[3] Vitamin B2 is synthesized from GTP and ribulose 5-phosphate among plants, yeast and many microorganisms. The reaction pathway begins with the opening of the imidazole ring of GTP and the removal of the phosphate residues. Deamination, reduction and removal of the remaining phosphate results in 5-amino-6-ribitylamino-2,4-pyrimidinone. This compound is reacted with 3,4-dihydroxy-2-butanone 4-phosphate to lead to the bicyclic molecule 6,7-dimethyl-8-ribitilumazine. This compound is converted to tricyclic riboflavin by immobilization transfer of 4-carbon units.
[4] Vitamin B2 occurs in many plants and meats, and to a lesser extent in grain products. The daily vitamin B2 requirement of an adult is about 1.4 to 2 mg. The major breakdown products of coenzymes FMN and FAD in humans are also riboflavin, which is released on its own.
[5] Thus, vitamin B2 is an important dietary substance for humans and animals. Thus, there is an effort to make vitamin B2 available on an industrial scale. Thus, the synthesis of vitamin B2 by microbiological pathways has been proposed. Microorganisms that can be used for this purpose are, for example, Bacillus subtilis , Streptococcus eremothesium ashviy, Ashvia goshpi , and yeast Candida flareri and Saccharomyces cerevisiae . Nutritional media used for this purpose include molasses or vegetable oils, inorganic salts, amino acids, animal or vegetable peptones and proteins, and vitamin adducts as carbon sources. In a sterile aerobic immersion method, yields of at least 10 g of vitamin B2 per liter of culture liquid medium are obtained within a few days. Good aeration of the culture, careful agitation and temperature setting below about 30 ° C are required. The biomass is removed, evaporated and the concentrate is dried to give a product rich in vitamin B2.
[6] Microbiological production of vitamin B2 is described, for example, in WO-A-92 / 01060, EP-A-0 405 370 and EP-A-0 531 708.
[7] A sample survey of the importance, development, production, biosynthesis and use of vitamin B2 can be found, for example, in Ullmann's Encyclopaedia of Industrial Chemistry, volume A27, pages 521 et seq.
[8] The cell wall and cytoskeleton of eukaryotic cells are particularly provided to maintain external and internal structures. The function of these components is similar to that of tent cloths and appropriate tent sticks. However, structures and compositions can be affected by external factors such as temperature and pH, but also internal factors such as cells, since the cytoskeleton of viable cells is not rigid and flexible and can adapt to the demands of growth and environmental conditions. It may be influenced by the ATP content or the ion concentration of.
[9] Fungal cell walls play a crucial role during growth, development, or fungal environment and interaction with other cells. Its main function is to protect the cells from protection, i.e. osmotic pressure, chemical or biological damage. However, cell walls are also involved in morphological responses, antigen expression, adhesion and cell-cell interactions. Fungal cell walls consist of a mixture of various polymers. The two categories are distinguished in this relationship. First, the so-called structural polymers that are responsive to the stiffness of the structure and the second embedded matrix polymer that ensures pressure resistance. For most fungi, the most important components of the cell wall are chitin, glucan and manno-protein. Among them, chitin and glucan have structural functions. Cell wall synthesis occurs by combining the individual components at various stages. Synthesis inside the cell or at the cell membrane / wall boundary layer is initially necessary for the individual components. After all the polymer is secreted into the expansion wall, loose assembly is initially formed through molecular interactions and tightly linked with covalent bonds.
[10] The cytoskeleton, in contrast, is a collaborative network of linear polymers linked to different cellular structures through various molecules. The organization and nature of this network makes precise occurrence-dependent and functional control. The main structural components of the cytoskeleton are formed by actin filaments (F actin), microtubules and intermediate filaments. Cytosols can be compared more with highly organized gels than homogeneous solutions, and the composition of the gels can exhibit significant differences in different regions of the cell. The cytoskeleton plays an important role in this structuring as well as cell division and organelle transport. In this regard, in a figurative sense, it takes over the function of the track as the most diverse cellular components are moved by cell motors such as dynein or kinesin.
[11] Unlike cell wall structures, the structures of the cytoskeleton are not characterized by the formation of covalent bonds. It is characterized by "dynamic instability", as in the case of microtubules, because it must have significantly greater flexibility. Tubulin subunits are polymerized with the aid of GTP. However, because GTP has the property of breaking down into DP + Pi under physiological conditions in cells, the structure of the microtubules must also be synthesized continuously to weaken and then degrade again. Microtubule-associated protein (MAP) can allow cells to achieve greater or controllable stabilization of microtubules. MAP has a high or low affinity depending on the degree of phosphorylation and hence the adjustable stabilizing effect on the microtubules.
[12] The polymerization of microfilaments from actin and the regulation of the stability of these polymers in cells occur similarly to tubulin. On the other hand, the polymerization process is increased by ATP. Actin-binding proteins affect the construction and breakage of microfilaments and can even block actin polymerization, as in the case of propylrin.
[13] There is extensive restructuring during the development-specific or environment-related changes in the form of fungi, for example during cell wall synthesis and cytoskeletal construction during germination or development of fruiting bodies or gastrointestinal tracts, with extremely precise time and space control. The basic structural backbone of cells is of substantial importance for cell safety and vehicle transport and forms the basic requirements for biomass production.
[14] For a more detailed description of cell wall construction and cytoskeletal structuring, see Wessels, J.G.H. (1990), Role of cell wall architecture in fungal tip growth generation. In: Heath I.B. (ed) Tip growth in plant and fungal cells. Academic Press, San Diego, pp 1-29; Heath I.B. and Heath M.C. (1978), Microtubules and organelle movement in rust fungus Uromyces phaseoli var. Vignae. Cytobiologie 16: 393-411; McConnel S.J., Yaffe M.P. (1993), Intermediate filament formation by a yeast protein essential for organelle inheritance. Science 260: 687-689; Esser K. und Lemke P.A. (ed) Mycota-A comprehensive Treatise on fungi as experimental systems for basic and applied research. Springer-Verlag, Berlin; Voet D. und Voet J.G. (ed) Biochemie. VCH, Weinheim, each of which is incorporated herein by reference.
[15] To preferably having a modified cell skeleton or a modified cell wall is Ashdod via genus, especially producing microorganism of Ashdod via Ghosh blood grid cell walls and (or) cell synthesis of the skeleton, for example, together with the modification of the external influences The use of genes related to (higher) resistance has not yet been described.
[16] It is an object of the present invention to provide novel targets that affect metabolic processes in the microorganisms of the genus Ashvian, in particular Ashbian goshpi . The aim is to optimize certain metabolic pathways, especially among these microorganisms. A further aim is to improve vitamin B2 production with these microorganisms.
[17] The inventors have found that this object is achieved by providing a coding nucleic acid sequence up- or downstream regulated in Ashvia Goshpi during vitamin B2 production and in particular the following nucleic acid sequence (results from the help of the MPSS assay method described in detail in the experimental section). Based on):
[18] a) a nucleic acid sequence encoding a protein having the function of a cell-wall precursor protein, preferably upstream.
[19] In a preferred embodiment of this aspect of the invention, DNA clones encoding the characteristic sub-sequences of the nucleic acid sequences of the invention and having the internal designation "oligo 8" were isolated.
[20] In a further preferred embodiment the DNA clones encoding the complete sequence of the nucleic acid of the invention according to the invention and having the internal designation "oligo 8v" were isolated.
[21] One aspect of the invention relates to a polynucleotide comprising the nucleic acid sequence set forth in SEQ ID NO: 1. A further aspect of the invention relates to a polynucleotide comprising the nucleic acid sequence shown in SEQ ID NO: 4 or a fragment thereof. Polynucleotides are of the genus Ashbian, in particular A. It can preferably be isolated from the microorganisms of Goshpie . The invention further relates to polynucleotides complementary thereto; And sequences derived from these polynucleotides through degeneracy of the genetic code.
[22] Inserts of "Uplift 8" and "Uplift 8v" are S. It has a MIPS tag "Cwp1" with significant homology to the Celebi from Asia. The insert has the nucleic acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 4. Amino acid sequences or amino acid sub-sequences derived from the complementary strand to SEQ ID NO: 1 or the coding strand shown in SEQ ID NO: 4 are described in Shimoni H., et al., In J. Biochem. 118: 302-311 (1995) . Of from three to Levy cyano cell-wall precursor has a protein Cwp1 with significant sequence homology.
[23] b) a nucleic acid sequence, preferably upstream regulated, that encodes a protein having the function of serine-threonine kinase.
[24] In a preferred embodiment of this aspect of the invention, DNA clones encoding the characteristic sub-sequences of the nucleic acid sequences of the invention and having the internal designation "up and 25/39" are isolated.
[25] In a further preferred embodiment a DNA clone encoding the complete sequence of a nucleic acid of the invention and having the internal designation "up and 25 / 39v" was isolated according to the invention.
[26] One aspect of the invention relates to a polynucleotide comprising the nucleic acid sequence set forth in SEQ ID NO: 8. A further aspect of the invention relates to a polynucleotide comprising a nucleic acid sequence set forth in SEQ ID NO: 10 or a fragment thereof. This polynucleotide is preferably of the genus Ashbian, in particular A. The present invention, which can be isolated from Gossipy 's microorganisms, further comprises polynucleotides complementary thereto; And sequences derived from these polynucleotides through degeneracy of the genetic code.
[27] Inserts of "up 25/39" and "up 25 / 39v" are S. Three have a MIPS tag "ARK1" with significant homology to the levy from Asia. The insert has the nucleic acid sequence set forth in SEQ ID NO: 8 or SEQ ID NO: 10. An amino acid sequence or amino acid partial-sequence derived from the complementary strand corresponding to SEQ ID NO: 8 or the coding strand shown in SEQ ID NO: 10 is designated as S. a. Has significant sequence homology with serine-threonine kinase from Serevisiae.
[28] c) a nucleic acid sequence encoding, preferably upstream, a protein having the function of a GTPase-activated protein.
[29] In a preferred embodiment of this aspect of the invention, DNA clones encoding the characteristic sub-sequences of the nucleic acid sequences of the invention and having the internal designation "Uplift 46" are isolated.
[30] In a further preferred embodiment, the DNA clones encoding the complete sequence of the nucleic acid of the invention according to the invention and having the internal designation "Uplift 46v" were isolated.
[31] One aspect of the invention relates to a polynucleotide comprising the nucleic acid sequence set forth in SEQ ID NO: 12. A further aspect of the invention relates to a polynucleotide comprising a nucleic acid sequence shown in SEQ ID NO: 15 or a fragment thereof. Polynucleotides are of the genus Ashbian, in particular A. It can preferably be isolated from the microorganisms of Goshpie . The invention further relates to polynucleotides complementary thereto; And sequences derived from these polynucleotides through degeneracy of the genetic code.
[32] Inserts of "Uplift 46" and "Uplift 46v" are S. Years of age have a MIPS tag "BUD2 / CLA2" with significant homology from the Levi cyano. The insert has the nucleic acid sequence set forth in SEQ ID NO: 12 or SEQ ID NO: 15. The amino acid sequence or amino acid partial-sequence derived from the complementary strand corresponding to SEQ ID NO: 12 or the coding strand shown in SEQ ID NO: 15 is selected from S. a. With GTPase- activating protein and significant sequence homology to three Levy from cyano, especially literature in [Park H.-O., et al, Nature 365. 269-274, (1993)] BUD2 / Rsr1 described in Homology with the BUD2-encoding GTPase-activated protein.
[33] d) a nucleic acid sequence encoding, preferably upstream, a protein having a function of actin overexpression resistance.
[34] In a preferred embodiment of this aspect of the invention, DNA clones encoding the characteristic sub-sequences of the nucleic acid sequences of the invention and having the internal designation "oligo 103" were isolated.
[35] In a further preferred embodiment, the DNA clones encoding the complete sequence of the nucleic acid of the invention according to the invention and having the internal designation "oligo 103v" were isolated.
[36] One aspect of the invention relates to a polynucleotide comprising a nucleic acid sequence set forth in SEQ ID NO: 17. A further aspect of the invention relates to a polynucleotide comprising the nucleic acid sequence set forth in SEQ ID NO: 19 or a fragment thereof. Polynucleotides are of the genus Ashbian, in particular A. It can preferably be isolated from the microorganisms of Goshpie . The invention further relates to polynucleotides complementary thereto; And sequences derived from these polynucleotides through degeneracy of the genetic code.
[37] Inserts of "Uplift 103" and "Uplift 103v" are S. It has a MIPS tag "Aor1" with significant homology to the Celebi from Asia. The insert has the nucleic acid sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 19. An amino acid sequence or amino acid sub-sequence derived from the complementary strand corresponding to SEQ ID NO: 17 or the coding strand shown in SEQ ID NO: 19 has actin overexpression resistance or contributes to this resistance . Three cyano Levy has a protein with significant sequence homology from.
[38] e) a nucleic acid sequence encoding a protein having the function of a Nuf1p-like protein, preferably downstream regulated.
[39] In a preferred embodiment of this aspect of the invention, DNA clones encoding the characteristic sub-sequences of the nucleic acid sequences of the invention and having the internal designation "up and 128" are isolated.
[40] In a further preferred embodiment, DNA clones with the internal designation "up and 128v" have been encoded which encode the complete sequence of the nucleic acid of the invention according to the invention.
[41] One aspect of the invention relates to a polynucleotide comprising a nucleic acid sequence set forth in SEQ ID NO: 21. A further aspect of the invention relates to a polynucleotide comprising the nucleic acid sequence set forth in SEQ ID NO: 23 or a fragment thereof. Polynucleotides are of the genus Ashbian, in particular A. It can preferably be isolated from the microorganisms of Goshpie . The invention further relates to polynucleotides complementary thereto; And sequences derived from these polynucleotides through degeneracy of the genetic code.
[42] Inserts of "Uplift 128" and "Uplift 128v" are S. Years of age have a MIPS tag "Ykl179c" with significant homology from the Levi cyano. The insert has the nucleic acid sequence set forth in SEQ ID NO: 21 or SEQ ID NO: 23. The amino acid sequence or amino acid portion-sequence derived from the coding strand is S. a. Has a Nuf1p- like proteins and significant sequence homology to three Levy from cyano (lit. [Wiemann S., et al, Yeast 9:. 1343-1348 (1993)] reference).
[43] f) a nucleic acid sequence encoding, preferably upstream, a protein having a function of calponin or calponin-homologous protein.
[44] In a preferred embodiment of this aspect of the invention, DNA clones encoding the characteristic sub-sequences of the nucleic acid sequences of the invention and having the internal designation "Upload 150" were isolated.
[45] In a further preferred embodiment, DNA clones having been encoded according to the invention encoding the complete sequence of the nucleic acids of the invention and having the internal designation "up and 150v".
[46] One aspect of the invention relates to a polynucleotide comprising the nucleic acid sequence set forth in SEQ ID NO: 26. A further aspect of the invention relates to a polynucleotide comprising the nucleic acid sequence set forth in SEQ ID NO: 28 or a fragment thereof. Polynucleotides are of the genus Ashbian, in particular A. It can preferably be isolated from the microorganisms of Goshpie . The invention further relates to polynucleotides complementary thereto; And sequences derived from these polynucleotides through degeneracy of the genetic code.
[47] Inserts of "Uplift 150" and "Uplift 150v" are S. It has a MIPS tag "Scp1" with significant homology to the Celebi from Asia. The insert has the nucleic acid sequence set forth in SEQ ID NO: 26 or SEQ ID NO: 28. The amino acid sequence or amino acid partial-sequence derived from the coding strand is S. Celebi Asian sword or knife ponin ponin from the - has a homogeneous protein with significant sequence homology.
[48] g) a nucleic acid sequence encoding, preferably upstream, a protein essential for gastric mycelial development in Candida maltosa.
[49] In a preferred embodiment of this aspect of the invention, DNA clones encoding the characteristic sub-sequences of the nucleic acid sequences of the invention and having the internal designation "oligo 177" were isolated.
[50] In a further preferred embodiment, the DNA clones encoding the complete sequence of the nucleic acids of the invention according to the invention and having the internal designation "up and 177v" were isolated.
[51] One aspect of the invention relates to a polynucleotide comprising the nucleic acid sequence set forth in SEQ ID NO: 30. A further aspect of the invention relates to a polynucleotide comprising a nucleic acid sequence shown in SEQ ID NO: 34 or a fragment thereof. Polynucleotides are of the genus Ashbian, in particular A. It can preferably be isolated from the microorganisms of Goshpie . The invention further relates to polynucleotides complementary thereto; And sequences derived from these polynucleotides through degeneracy of the genetic code.
[52] Inserts of "Raise 177" and "Raise 177v"Candida MaltosaHas significant homology with the MIPS tag "EPD1" from. The insert has the nucleic acid sequence set forth in SEQ ID NO: 30 or SEQ ID NO: 34. The complementary strand or sequence corresponding to SEQ ID NO: 30 The amino acid sequence that can be derived from the coding strand shown in number 34 isCandida MaltosaProtein from, in particularSeed. MaltosaHave significant sequence homology to proteins essential for the development of gastric mycelia (see Nakazawa T., et al., J. Bacteriol., 180 (8), 2079-2086, (1998)). Like S. It was possible to establish homology to the corresponding protein from Cerevisiae.
[53] h) a nucleic acid sequence encoding, preferably downstream regulated, a protein having the function of a protein that interacts with actin.
[54] In a preferred embodiment of this aspect of the invention, DNA clones encoding the characteristic sub-sequences of the nucleic acid sequences of the invention and having the internal designation "oligo 145" are isolated.
[55] In a further preferred embodiment, the DNA clones encoding the complete sequence of the nucleic acid of the invention according to the invention and having the internal designation "oligo 145v" were isolated.
[56] One aspect of the invention relates to a polynucleotide comprising a nucleic acid sequence set forth in SEQ ID NO: 36. A further aspect of the invention relates to a polynucleotide comprising a nucleic acid sequence shown in SEQ ID NO: 38 or a fragment thereof. Polynucleotides are of the genus Ashbian, in particular A. It can preferably be isolated from the microorganisms of Goshpie . The invention further relates to polynucleotides complementary thereto; And sequences derived from these polynucleotides through degeneracy of the genetic code.
[57] Inserts of "Uplift 145" and "Uplift 145v" are S. Years of age have a MIPS tag "Aip2" with significant homology from the Levi cyano. The insert has the nucleic acid sequence set forth in SEQ ID NO: 36 or SEQ ID NO: 38. The amino acid sequence or amino acid sub-sequence derived from the coding strand is used to interact with actin . It has three proteins with significant sequence homology to Levy from cyano (reference [Chelstowska A., et al., Yeast 15 (13), 1377-1391 (1999)]).
[58] A further aspect of the present invention relates to oligonucleotides that hybridize under particularly stringent conditions with one of the above polynucleotides.
[59] The present invention further relates to polynucleotides that hybridize with one of the oligonucleotides of the invention and encode a gene product from a microorganism of the genus Ashbia or a functional equivalent of this gene product.
[60] The invention further relates to a polypeptide or protein encoded by the aforementioned polynucleotides; And SEQ ID NO: 2, 3, 5, 6, 7, 9, 11, 13, 14, 16, 18, 20, 22, 24, 25, 27, 29, 31, 32, 33, 35, 37 or SEQ ID NO: 39 Peptide fragments thereof having an amino acid sequence comprising at least 10 contiguous amino acid residues shown in; And to functional equivalents of the polypeptides or proteins of the invention.
[61] In this regard, the functional equivalent is at least 1, such as 1-30 or 1-20 or 1-10 sequence positions, without the originally observed protein function that can be induced by sequence comparison with other proteins that are lost. Their amino acid sequences, through addition, insertion, substitution, deletion or inversion, differ from the products specifically disclosed herein. Thus, functional equivalents may be equivalents having essentially the same, higher or lower activity compared to natural protein.
[62] Further aspects of the invention include an expression cassette for recombinant production of a protein of the invention comprising one of the nucleic acid sequences defined above and operably linked to one or more regulatory nucleic acid sequences; And to a recombinant vector comprising one or more such expression cassettes of the invention.
[63] Also provided in accordance with the present invention are prokaryotic or eukaryotic hosts transformed with one or more vectors of this type. Preferred embodiments modulate (eg, inhibit or overexpress) functional expression of one or more genes encoding a polypeptide of the invention as defined above; Or prokaryotic or eukaryotic hosts that reduce or increase the biological activity of a polypeptide as defined above. Preferred hosts are asymptococci, in particular the Ashvian genus, preferably A. Selected from those of the Gossipi line.
[64] Modulation of gene expression in this sense can be effected, for example, by its inhibition through blockade of a step (especially transcription or translation) during expression or by certain overexpression of a gene (eg, modification of regulatory sequences or an increase in the number of copies of a coding sequence). Through) includes everything.
[65] A further aspect of the invention relates to the use of an expression cassette of the invention, a vector of the invention or a host of the invention for the microbiological production of vitamin B2 and / or precursors and / or derivatives thereof.
[66] A further aspect of the invention relates to the use of the expression cassette of the invention, the vector of the invention or the host of the invention for recombinant production of a polypeptide of the invention as defined above.
[67] Also provided in accordance with the present invention are methods of detecting or identifying effector targets for modulating the microbiological production of vitamin B2 and / or precursors and / or derivatives thereof. It is used to modify vitamin B2 and / or its precursors and / or derivatives thereof using effectors that interact (eg, non-covalently bound) with a target selected from a polypeptide of the invention or a nucleic acid sequence encoding the same as defined above. Treatment of microorganisms which can be produced microbiologically; Identification of effect factors on microbiological production of vitamin B2 and / or precursors and / or derivatives thereof; And isolation of the target as the case may be. In this case it is preferably confirmed by direct comparison with microbiological vitamin B2 production in the absence of effectors under different identification conditions.
[68] A further aspect of the present invention provides a microorganism capable of microbiologically producing vitamin B2 and / or its precursors and / or derivatives with a target selected from a polypeptide of the invention or a nucleic acid sequence encoding the same, as defined above. To a method for modulating the microbiological production (relative to amount (and) or rate) of vitamin B2 and / or its precursors and / or derivatives thereof.
[69] Preferred examples of the above-described effectors that should be mentioned include:
[70] a) an antibody or antigen-binding fragment thereof;
[71] b) a polypeptide ligand different from a) and interacting with a polypeptide of the invention;
[72] c) low molecular weight effectors modulating the biological activity of the polypeptides of the invention;
[73] d) there is an antisense nucleic acid sequence which interacts with the nucleic acid sequence of the present invention.
[74] The invention likewise relates to the aforementioned effectors having specificity for at least one target according to the invention as defined above.
[75] A further aspect of the invention relates to vitamin B2 and (), wherein the host as defined above is cultured under conditions favorable for the production of vitamin B2 and / or precursors and / or derivatives thereof, and the desired product (s) is isolated from the culture mixture. Or) microbiological production of the precursors and / or derivatives thereof. In this connection it is preferred to treat the host with the effectors defined above before and / or during its culture. Preferred hosts in this case are the genus Ashvian ; In particular, it is selected from the microorganisms of the genus Ashvian transformed as described above.
[76] The final aspect of the invention relates to the use of a polynucleotide or polypeptide of the invention as a target for modulating the production of vitamin B2 and / or its precursors and / or derivatives in microorganisms of the genus Ashbia .
[77] 1 shows amino acid portion-sequences of the invention (corresponding to the complementarity strand for positions 1092-595 in SEQ ID NO: 1) (parent sequence) and S. a. The alignment between the sub-sequences (subsequences) of the MIPS tag Cwp1 from Serevisiae is shown. The same sequence position is indicated between the two sequences. Similar sequence positions are labeled with "+".
[78] 2 shows amino acid portion-sequences of the invention (corresponding to the complementarity strand for positions 1067-84 in SEQ ID NO: 8) (parent sequence) and S. a. The alignment between the sub-sequences (subsequences) of the MIPS tag ARK1 from Cerevisiae is shown. The same sequence position is shown between two sequences in each case. Similar sequence positions are labeled with "+".
[79] Figure 3A shows amino acid portion-sequences (corresponding to complementarity strands for positions 475 to 353 in SEQ ID NO: 12) (parent sequence) and S. The alignment between the sub-sequences (subsequences) of the MIPS tag BUD2 / CLA2 from Serevisiae is shown. Figure 3B shows amino acid portion-sequences of the invention (corresponding to the complementarity strand for positions 351 to 1 in SEQ ID NO: 12) (parent sequence) and S. a. The alignment between the sub-sequences (subsequences) of the MIPS tag BUD2 / CLA2 from Serevisiae is shown. The same sequence position is indicated between the two sequences. Similar sequence positions are labeled with "+".
[80] 4 shows amino acid portion-sequences of the invention (corresponding to the complementarity strands for positions 933-157 in SEQ ID NO: 17) (parent sequence) and S. a. The alignment between the sub-sequences (subsequences) of the MIPS tag Aor1 from Serevisiae is shown. The same sequence position is indicated between the two sequences. Similar sequence positions are labeled with "+".
[81] FIG. 5 shows amino acid portion-sequences (corresponding to strands for positions 117-794 in SEQ ID NO: 21) (parent sequence) and S. The alignment between the sub-sequences (subsequences) of the MIPS tag Ykl179c from Serevisiae is shown. The same sequence position is indicated between the two sequences. Similar sequence positions are labeled with "+".
[82] 6 shows amino acid portion-sequences (corresponding to strands for positions 438 to 767 in SEQ ID NO: 26) of the invention (parent sequence) and S. a. The alignment between the sub-sequences (subsequences) of the MIPS tag Sccp from Serevisiae is shown. The same sequence position is indicated between the two sequences. Similar sequence positions are labeled with "+".
[83] 7A shows amino acid portion-sequences (corresponding to complementarity strands for positions 983 to 651 in SEQ ID NO: 30) (parent sequence) and seed of the present invention . The alignment between the sub-sequences (subsequences) of the MIPS tag EPD1 from Maltosa is shown. 7B shows amino acid portion-sequences of the invention (corresponding to the complementarity strand for positions 661 to 596 in SEQ ID NO: 30) (parent sequence) and seed. The alignment between the sub-sequences (subsequences) of the MIPS tag EPD1 from Maltosa is shown. 7C shows amino acid portion-sequences of the invention (corresponding to the complementarity strand for positions 591 to 1 in SEQ ID NO: 30) (parent sequence) and seed. The alignment between the sub-sequences (subsequences) of the MIPS tag EPD1 from Maltosa is shown. The same sequence position is indicated between the two sequences. Similar sequence positions are labeled with "+".
[84] 8 shows amino acid portion-sequences (corresponding to strands for positions 2 to 148 in SEQ ID NO: 36) (parent sequence) and S. of the present invention . The alignment between the sub-sequences (subsequences) of the MIPS tag Aip2 from Serevisiae is shown. The same sequence position is indicated between the two sequences. Similar sequence positions are labeled with "+".
[85] Nucleic acid molecules of the invention encode a polypeptide or protein referred to herein as a protein of cell wall or cytoskeleton construction (eg having activity related to cell wall synthesis or cytoskeletal construction) or simply “CC protein”. These CC proteins have the function of, for example, the synthesis or restructuring of the cell wall or cytoskeleton associated with developmental-specific or environmental-related changes in cell morphology. For example, in which can be used for cloning Ashdod via Ghosh P, as disclosed in (Wright and Philipsen (1991) Gene , 109, 99-105) vector, and this. Because of the usefulness of the genetic engineering techniques of Gossipy and related yeast species, the nucleic acid molecules of the present invention are particularly useful in these organisms, particularly A. It can be used in their genetic manipulations to make Gossipi a better and more effective producer of vitamin B2 and / or their precursors and / or derivatives. This improved production or efficiency may arise from the direct results of the genetic manipulations of the invention or from the indirect results of such manipulations.
[86] The present invention is related to the basis of the provision of new molecules referred to herein as CC CC protein nucleic acid and, in particular, constructed cell wall and cytoskeleton of Ashdod via Ghosh blood (e. G., Synthetic or restructuring of the cell wall and cytoskeleton). a. CC active molecules of the present invention in Ghosh blood influences the production of vitamin B2 through this organism. Preferably the A. CC protein of the present invention is associated . It modulates the CC molecular activity of the present invention such that the metabolic and / or energy pathways of Gossipy are regulated in relation to the yield, production and / or efficiency of vitamin B2, which is a . Adjust, directly or indirectly, the yield, production and / or efficiency of vitamin B2 in Gospy .
[87] Nucleic acid sequences provided by the present invention can be isolated from, for example, the genome of the Ashvia Gossipi line, which is freely available under the number ATCC 10895 from the American Type Culture Collection.
[88] Improving Vitamin B2 Production:
[89] a. There are a number of possible mechanisms by which the yield, production and / or efficiency of vitamin B2 by the Goshpie strain can be directly affected through changes in the amount and / or activity of the CC protein of the invention.
[90] Thus, specific regulation of metabolism can increase or optimize the production efficiency of the desired product (eg, fine chemicals) relative to the competition product. In addition, cells can be made more resistant to external influences to increase viability and thus productivity in fermenters.
[91] Mutagenesis of one or more CC proteins of the present invention may be characterized as A. It may also be derived from CC proteins with controlled (increased or reduced) activity which indirectly affects the production of the desired product. This is possible, for example, with the help of CC proteins that are suitable for the stability of cells to specific environmental or culture conditions and for vehicle transport in cells to maintain essential metabolic process functions. These processes include the biosynthesis of compounds necessary for cell wall construction, transcription, translation, cell growth and differentiation (eg, nucleotides, amino acids, vitamins, lipids, etc.) in addition to the biosynthesis of the product (Lengeler et al. (1999) Biology of Procaryotes , Thieme Verlag, Stuttgart). The growth and proliferation of these modified cells can be improved to increase the viability of the cells in large-scale cultures, and also the rate of their differentiation can be improved so that a relatively large number of producing cells can survive in fermentor broth. Yield, production or yield can be increased at least because there are multiple viable cells, each producing a desired product.
[92] Polypeptides:
[93] The present invention relates to a polypeptide comprising an amino acid sequence as described above or a characteristic sub-sequence thereof and / or encoded by a nucleic acid sequence described herein.
[94] The invention likewise includes the "functional equivalents" of the novel polypeptides specifically disclosed.
[95] A “functional equivalent” or analog of a specifically disclosed polypeptide is a polypeptide that differs from the specifically disclosed polypeptide for the purposes of the present invention but still has the desired biological activity (eg, substrate specificity).
[96] By "functional equivalent" according to the invention is meant especially mutants having amino acids different from the sequences specifically mentioned at one or more of the above mentioned sequence positions but nevertheless having one of the biological activities mentioned above. Thus, a "functional equivalent" includes a mutant obtainable by addition, substitution, deletion and / or inversion of one or more amino acids and occurs at any sequence position to induce a mutant having the characteristic profile of the present invention. The above modification is possible. Functional equivalence is also particularly present when there is a qualitative match of the reactive pattern between the mutant and the unmodified polypeptide, ie when the conversion rates of the same substrate are different.
[97] In the sense "functional equivalent" is also described polypeptide precursors, and functional derivatives and salts of polypeptides. The term "salt" means both salts of carboxyl groups and acid addition salts of amino groups in the protein molecules of the invention. Salts of the carboxyl groups can be prepared in a manner known per se and include inorganic salts such as sodium, calcium, ammonium, iron and zinc salts, and salts with organic bases such as amines such as triethanolamine, arginine, lysine, blood Ferridine and the like. Acid addition salts such as salts with inorganic acids such as hydrochloric acid or salts with sulfuric acid and organic acids such as acetic acid and oxalic acid are also aspects of the invention.
[98] "Functional derivatives" of the polypeptides of the invention may also be prepared by techniques known at the functional amino acid side chains or at the N- or C-terminus thereof. Such derivatives include, for example, amides of the carboxyl groups which can be obtained by reaction with aliphatic esters of a carboxyl group, ammonia or primary or secondary amines; N-acyl derivatives of free amino groups prepared by reaction with acyl groups; Or O-acyl derivatives of free hydroxyl groups prepared by reaction with acyl groups.
[99] “Functional equivalents” naturally also include polypeptides obtainable from other organisms and naturally occurring variants. For example, homologous sequence regions can be found by sequence comparison and equivalent enzymes can be established based on the specific needs of the present invention.
[100] A “functional equivalent” likewise comprises a fragment, preferably a single domain or sequence motif, of a polypeptide of the invention, eg having the desired biological function.
[101] Additionally, a "functional equivalent" means one or more of the above-described polypeptide sequences or one or more functional equivalents and functional N- or C-terminal linkages therefrom that are functionally different from one another (ie, have minor mutual damage of fusion protein site function). Fusion proteins with different heterologous sequences. Non-limiting examples of such heterologous sequences include, for example, signal peptides, enzymes, immunoglobulins, surface antigens, receptors or receptor ligands.
[102] According to the present invention "functional equivalent" includes homologues of specifically disclosed proteins. These have at least 60%, preferably at least 75%, in particular at least 85%, such as 90%, 95% or 99% homology to one of the specifically disclosed sequences, wherein homology is found in Pearson and Lipman, Proc. Natl.Acad, Sci. (USA) 85 (8), 1988, 2444-2448).
[103] Where protein glycosylation can be made, equivalents of the invention include proteins of the type defined above in the deglycosylated or glycosylated form and in the modified form obtainable by altering the glycosylation pattern.
[104] Homologs of proteins or polypeptides of the invention can be produced by mutagenesis, eg, point mutations or partial cleavage of proteins. As used herein, the term “homolog” refers to a variant form of a protein that acts as an agent or antagonist of protein activity.
[105] Homologs of the proteins of the invention can be identified by screening combinatorial libraries of mutants, such as partially truncated mutants. For example, it is possible to produce diversified libraries of protein variants by combinatorial mutagenesis at the nucleic acid level, such as by enzymatic ligation of a mixture of synthetic oligonucleotides. There are a number of methods that can be used to prepare libraries of possible homologs from degenerate oligonucleotide sequences. Chemical synthesis of degenerate gene sequences can be performed in an automated DNA synthesizer, and the synthetic genes can then be ligated into a suitable expression vector. Using a degenerate set of genes makes it possible to provide all the sequences encoding the desired set of possible protein sequences in one mixture. Methods of synthesis of degenerate oligonucleotides are known to the skilled person (see, for example, Narang, SA (1983) Tetrahedron 39: 3; Itakura et al. (1984) Annu. Rev. Biochem. 53: 323; Itakura et al) , (1984) Science 198: 1056; Ike et al. (1983) Nucleic Acid Res. 11: 477).
[106] In addition, libraries of protein codon fragments can be used to produce a diversified population of protein fragments for the screening and subsequent selection of protein homologs of the invention. In one embodiment the double-stranded PCR fragments of the coding sequence are treated with nucleases under conditions in which nicking occurs only about once per molecule, denaturing the double-stranded DNA and regenerating the DNA to produce different nicked products. Forming double-stranded DNA, which may comprise a sense / antisense pair of, removing the single-stranded compartment from the newly formed double helix by treatment with S1 nuclease, and ligation of the resulting fragment library into an expression vector to encode a coding sequence fragment. A library of can be prepared. This method can lead to expression libraries encoding N-terminal, C-terminal and internal fragments having proteins of different sizes of the present invention.
[107] Several techniques are known in the prior art for the screening of gene products from combinatorial libraries, which can be prepared by point mutations or partial cleavage, and for the screening of cDNA libraries for gene products having selected properties. These techniques can be adapted by instant screening of gene libraries that can be prepared by combinatorial mutagenesis of the homologues of the invention. The most commonly used techniques for screening large gene libraries to analyze high-throughput are cloning the gene library into a replicable expression vector, transforming the appropriate cells into the resulting vector library, and identifying the gene from which the product is detected. Isolation of the encoding vector includes expressing the combination gene under conditions that facilitate detection of the desired activity. Cyclic total mutagenesis (REM), a technique for increasing the number of functional mutants in a library, can be used in combination with screening tests to identify homologues (Arkin and Yourvan (1992) PNAS 89: 7811-7815; Delgrave et al. 1993) Protein Engineering 6 (3): 327-331).
[108] Recombinant preparation of the polypeptides of the invention is possible (see section below) or recombinant preparations of the polypeptides of the invention can be isolated using microbial organisms, especially microorganisms of the genus Ashvian, in natural form using conventional biochemical techniques (Cooper, TG, Biochemische Arbeitsmethoden, Verlag Walter de Gruyter, Berlin, New York or Scopes, R., Protein Purification, Springer Verlag, New York, Heidelberg, Berlin).
[109] Nucleic Acid Sequences:
[110] The invention also relates to nucleic acid sequences encoding one of the polypeptides (single- and double-stranded DNA and RNA sequences such as cDNA and mRNA), and their functional equivalents obtainable by, for example, artificial nucleotide analogues. It is about.
[111] The invention may be used for use as an isolated nucleic acid molecule encoding a polypeptide or protein of the invention or a biologically active compartment thereof, and as a hybridization probe or primer for identifying or amplifying, for example, the coding nucleic acid of the invention. All of the nucleic acid fragments.
[112] Nucleic acid molecules of the invention may additionally comprise untranslated sequences from 3 'and / or 5' of the gene coding region.
[113] An “isolated” nucleic acid molecule is isolated from other nucleic acid molecules present in the natural source of the nucleic acid and, moreover, when prepared by recombinant technology is substantially free of other cellular material or culture medium, or chemically synthesized when chemically synthesized or Other chemicals may be substantially free.
[114] Nucleic acid molecules of the invention can be isolated using standard techniques of molecular biology and sequence information provided in accordance with the invention. For example, cDNAs can be isolated from suitable cDNA libraries using one of the specifically disclosed complete sequences or their compartments as hybridization probes and standard hybridization techniques (as described, eg, Sambrook, J. , Fritsch, EF and Maniatis, T. Molecular Cloning: A Laboratory Manual.2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). In addition, nucleic acid molecules may comprise oligonucleotide primers prepared based on one of the disclosed sequences and comprise these sequences or sections thereof isolated by polymerase chain reaction. The nucleic acids amplified in this manner are cloned into suitable vectors. And can be characterized by DNA sequencing. Oligonucleotides of the invention corresponding to ME nucleotide sequences can also be prepared using standard synthetic methods, such as automated DNA synthesizers.
[115] The invention further encompasses nucleic acid molecules, or compartments thereof, that are complementary to specifically described nucleotide sequences.
[116] Nucleotide sequences of the present invention allow the preparation of probes and primers that can be used to identify and / or clone homologous sequences among other cell types and organisms. Such probes and primers are nucleotides that hybridize onto at least about 12, preferably at least about 25, such as 40, 50 or 75 contiguous nucleotides of the nucleic acid sequence sense strand or corresponding antisense strand of the invention under stringent conditions. It includes a sequence region.
[117] Additional nucleic acid sequences of the invention are derived from SEQ ID NOs: 1, 4, 8, 10, 12, 15, 17, 19, 21, 23, 26, 28, 30, 34, 36 or SEQ ID NO: 38, and one or more nucleotides By addition, substitution, insertion or deletion of a, it encodes a polypeptide that is different but still has the properties of the desired profile.
[118] The present invention also encompasses naturally occurring variants, such as splicing variants or allelic variants thereof, as well as nucleic acid sequences that include so-called silent mutations or are modified according to the codon usage of a particular source or host organism in comparison to the specifically mentioned sequences. Include. The present invention likewise relates to sequences obtainable by conservative nucleotide substitutions (ie, related amino acids are replaced with amino acids having the same charge, size, polarity and / or solubility).
[119] The invention also relates to molecules derived from nucleic acids specifically disclosed through sequence polymorphism. These genetic polymorphisms may exist because of natural variations between individuals within a population. These natural variants usually have 1-5% variation in the nucleotide sequence of the gene.
[120] The present invention additionally encompasses nucleic acid sequences that are hybridized or complementary to the coding sequences described above. These polynucleotides can be identified by genome or cDNA library screening and, where appropriate, amplified therefrom using suitable primers by PCR, and then isolated, for example, with suitable probes. There is another possibility of transforming suitable microorganisms with the polynucleotides or vectors of the invention, augmenting the microorganisms and thus polynucleotides, and then isolating these polynucleotides. There is a further possibility of synthesizing the polynucleotide of the present invention by chemical route.
[121] The ability to "hybridize" on polynucleotides means the ability of a polynucleotide or oligonucleotide to bind to most complementary sequences under stringent conditions while there is no nonspecific binding between non-complementary pairs under these conditions. For this purpose, this sequence should have complementarity of 70 to 100%, preferably 90 to 100%. Properties of complementarity sequences that can specifically bind to each other are used in PCR or RT-PCR, for example in the case of Northern or Southern blot techniques or primer binding. Oligonucleotides having a length of at least 30 base pairs are usually used for this purpose. Stringent conditions are for example 50-70 to elute nonspecifically hybridized cDNA probes or oligonucleotides in Northern blot techniques. ℃, preferably 60 to 65 Mean use of a wash solution at < RTI ID = 0.0 > C, < / RTI > for example 0.1 x SSC buffer (20 x SSC: 3M NaCl, 0.3M Na citrate, pH 7.0) with 0.1% SDS. In this case, only nucleic acids having a high degree of complementarity remain bound to each other as described above. The establishment of stringent conditions is known to the skilled person and is described, for example, in Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.
[122] A further aspect of the invention relates to antisense nucleic acids. It includes a nucleotide sequence that is complementary to a coding sense nucleic acid. Antisense nucleic acids can be complementary to the entire coding strand or just their compartments. In further embodiments, the antisense nucleic acid molecule is antisense to the non-coding region of the coding strand of the nucleotide sequence. The term "non-coding region" refers to a sequence partition called the 5'- and 3'-untranslated regions.
[123] Antisense oligonucleotides may be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 nucleotides in length. Antisense nucleic acids of the invention can be prepared by chemical synthesis and enzyme ligation reactions using methods known in the art. Antisense nucleic acids can be chemically synthesized using naturally occurring nucleotides or various modified nucleotides coordinated to increase the biological stability of the molecule or the physical stability of the double helix formed between the antisense and sense nucleic acids. Examples that can be used include phosphorothioate derivatives and acridine-substituted nucleotides. Examples of modified nucleotides that can be used to prepare antisense nucleic acids include, in particular, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hyoxanthin, xanthine, 4-acetylcytosine , 5- (carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylquauocin, inosine, N6- Isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7 -Methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylquausin, 5-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio -N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wabutoxosocin, pseudouracil, queuocin, 2-thiosa Itocin, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, methyl uracil-5-oxyacetate, 3- (3-amino-3-carboxypropyl) uracil, ( acp3) w and 2,6-diaminopurine. In addition, antisense nucleic acids can be produced biologically using expression vectors in which the nucleic acids are subcloned in the antisense direction.
[124] Antisense nucleic acid molecules of the invention are usually introduced into cells or produced in situ to hybridize to or bind to cellular mRNA and / or coding DNA to inhibit expression of the protein, e.g. by inhibition of transcription and / or translation. do.
[125] For example, antisense molecules can be modified to specifically bind to receptors or antigens expressed on selected cell surfaces through linkages of antisense nucleic acid molecules with peptides or antibodies that bind to cell surface receptors or antigens. Antisense nucleic acid molecules can also be introduced into cells using the vectors described herein. Preferred vector preparations for achieving adequate intracellular concentrations of antisense molecules are those in which the antisense nucleic acid molecules are under the control of strong bacterial, viral or eukaryotic promoters.
[126] In further embodiments, the antisense nucleic acid molecules of the invention are alpha-anomeric nucleic acid molecules. Alpha-anomeric nucleic acid molecules form specific double-stranded hybrids with complementary RNA with strands in the same direction as opposed to normal alpha units (Gaultier et al., (1987) Nucleic Acid Res. 15: 6625-6641 ). Antisense nucleic acid molecules additionally include 2′-O-methylribonucleotides (Inoue et al., (1987) Nucleic Acid Res. 15: 6131-6148) or chimeric RNA-DNA analogs (Inoue et al. (1987) FEBS Lett. 215 : 327-330).
[127] The present invention also relates to ribozymes. These are catalytic RNA molecules with ribonuclease activity capable of cleaving single-stranded nucleic acids such as complementary regions, such as mRNA. Thus, ribozymes (e.g., Hammerhead ribozymes (Haselhoff and Gerlach (1988) Nature 334: 585-591)) are described for catalytic cleavage of transcripts of the invention to inhibit translation of corresponding nucleic acids. Can be used). Ribozymes having specificity for the coding nucleic acids of the invention can be formed, for example, based on the cDNAs specifically disclosed herein. For example, derivatives of tetrahymena-L-19 IVS RNA can be prepared with the nucleotide sequence of the active site complementary to the nucleotide sequence cleaved in the coding mRNA of the present invention. (Eg, as compared to US-A-4 987 071 and US-A-5 116 742). Alternatively, mRNA can be used to select catalytic RNA with specific ribonuclease activity from a pool of RNA molecules (see, eg, Bartel, D., and Szostak, JW (1993) Science 261: 1411. -1418).
[128] Gene expression of the sequences of the invention may otherwise regulate regulatory regions (e.g., promoters and / or enhancers of the coding sequence) such that the transcription of the corresponding gene in the target cell can be blocked to form a triple helix structure. Can be inhibited by targeting nucleotide sequences complementary to (Helene, C. (1991) Anticancer Drug Res. 6 (6) 569-584; Helene, C. et al., (1992) Ann. NY Acad. Sci) 660: 27-36; and Maher., LJ (1992) Bioassays 14 (12): 807-815).
[129] Expression preparations and vectors:
[130] The invention further provides expression preparations comprising a nucleic acid sequence encoding a polypeptide of the invention under genetic control of a regulatory nucleic acid sequence; And one or more of these expression preparations. Such preparations of the invention preferably comprise promoter 5'-upstream from the specific coding sequence, and terminator sequence 3'-down, and, where appropriate, other general regulatory elements, each operably linked to the coding sequence, respectively. “Operative linkage” means a contiguous arrangement of a promoter, coding sequence, terminator and, where appropriate, other regulatory elements, in a manner that each of the regulatory elements may depend on the function of which the coding sequence is to be expressed. Examples of sequences that can be operably linked target sequences and enhancers, polyadenylation signals, and the like. Other regulatory elements include selectivity indicators, amplification signals, origin of replication, and the like. Suitable regulatory sequences are described, for example, in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990).
[131] In addition to the artificial regulatory sequence, it may be a native regulatory sequence still present before the actual structural gene. This natural regulation can be stopped by genetic modification if appropriate and the expression of the gene can be increased or decreased. However, the gene preparation may also have a simpler structure, that is to say that no additional regulatory signal is inserted before the structural gene and that the natural promoter with its regulation is not deleted. Instead, natural regulatory sequences are no longer regulated and are mutated to enhance or decrease gene expression. Nucleic acid sequences may be present in one or more copies of a gene preparation.
[132] Examples of promoters that can be used include cos, tac, trp, tet, trp-tet, lpp, lac, lpp-lac, lacIq, T7, T5, T3, gal, trc, ara, SP6, λ-PR or λ-PL Promoter (used advantageously for gram-negative bacteria); And Gram-positive promoters amy and SPO2, yeast promoter ADC1, MFα, AC, P-60, CYC1, GAPDH or plant promoter CaMV / 35S, SSU, OCS, lib4, usp, STLS1, B33, or or ubiquitin or paseolin There is a promoter. Particular preference is given to using inducible promoters such as photo- and in particular, temperature-inducible promoters such as the P _r P ₁ promoter. In principle all natural promoters having a regulatory sequence to be used are possible. It is also advantageously possible to use synthetic promoters.
[133] Such regulatory sequences are intended to enable specific expression of nucleic acid sequences. This may mean, for example, that a gene is only expressed or overexpressed or immediately expressed and / or overexpressed, depending on the host organism.
[134] In addition, regulatory sequences or factors preferably affect positively, thus increasing or decreasing expression. Thus, the enhancement of regulatory elements can be advantageously performed at the level of transcription using strong transcription signals such as promoters and / or enhancers. However, translation can also be enhanced, for example by improving the stability of the mRNA.
[135] Expression cassettes are prepared by fusing a suitable promoter to a suitable monooxygenase nucleotide sequence and terminator signal or polyadenylation signal. Conventional recombination and cloning techniques are described for this purpose in, for example, T. Maniatis, EF Fritsch and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982) and TJ Silhavy. , ML Berman and LW Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984) and Ausubel, FM et al., Current Protocols in Molecular Biology, Greene Publishing Assoc. And Wiley Interscience (1987)) Used as described.
[136] For expression in a suitable host organism, the recombinant nucleic acid preparation or gene preparation is advantageously inserted into a host-specific vector, allowing for optimal expression of the gene in the host. Vectors are well known to the skilled person and can be found, for example, in the "cloning vector" (Pouwels P. H. et al., Eds, Elsevier, Amsterdam-New York-Oxford, 1985). Vector also refers to plasmids and all other vectors known to the skilled person, such as phages, viruses such as SV40, CMV, baculovirus and adenoviruses, transposons, IS elements, pasmids, cosmids, and linear or circular DNA. These vectors can be autonomously replicated or chromosomal replicated among host organisms.
[137] Examples of suitable expression vectors that may be mentioned are the following vectors:
[138] Conventional fusion expression vectors such as pGEX (Pharmacia Biotech Inc; Smith, DB and Johnson, KS (1988) Gene 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) And pRIT 5 (Pharmacia, Piscataway, NJ ) (Glutathione S-transferase (GST), maltose E-binding protein and Protein A each are fused to recombinant target protein).
[139] Non-fusion protein expression vectors such as pTrc (Amann et al., (1988) Gene 69: 301-315) and pET 11d (Studier et al. Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California ( 1990) 60-89).
[140] Yeast S. Yeast expression vector for expression in the three Levy cyano, for example pYepSec1 (Baldari et al, (1987 ) Embo J. 6:. 229-234), pMFα (Kurjan and Herskowitz (1982) Cell 30: 933-943), pJRY88 (Schultz et al. (1987) Gene 54: 113-123) and pYES2 (Invitrogen Corporation, San Diego, Calif.). Methods for preparing vectors and vectors suitable for use in other fungi, such as filamentous fungi, are described in van den Hondel, CAMJJ & Punt, PJ (1991) "Gene transfer systems and Vector development for filamentous fungi, in: Applied Molecular Genetics of Fungi, JF Peberdy et al., Eds, pp. 1-28, Cambridge University Press: Cambridge).
[141] Baculovirus vectors that can be used to express proteins in insect cells that are cultured (eg, Sf9 cells) include the pAc series (Smith et al., (1983) Mol. Cell Biol .. 3: 2156-2165) and pVL series (Lucklow and Summers (1989) Virology 170: 31-39).
[142] Plant expression vectors such as Becker, D., Kemper, E., Schell, J. and Masterson, R. (1992) "New plant binary vector with selectable markers located proximal to the left border", Plant Mol. Biol. 20: 1195-1197 and Bevan, MW (1984) "Binary Agrobacterium vectors for plant transformation", Nucl. Acids Res. 12: 8711-8721.
[143] Mammalian expression vectors such as pCDM8 (Seed, B. (1987) Nature 329: 840) and pMT2PC (Kaufman et al. (1987) EMBO J. 6: 187-195).
[144] Additional suitable prokaryotic and eukaryotic cell expression systems are described in Sambrook, J., Fritsch, EF and Maniatis, T., Molecular cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
[145] Recombinant Microorganisms:
[146] Vectors of the invention can be used, for example, to produce recombinant microorganisms transformed with one or more vectors of the invention, and can be used to produce polypeptides of the invention. The recombinant preparations of the invention described above are advantageously introduced and expressed in a suitable host system. Cloning and transfection methods familiar to the skilled person, such as coprecipitation, protoplast fusion, electroshock, retroviral transfection and the like are preferably used to express the nucleic acid in a particular expression system. Suitable systems are described, for example, in Current Protocols in Molecular Biology, F. Ausubel et al., Eds, Wiley Interscience, New York 1997, or Sambrook et al. Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
[147] It is also possible to produce homologously recombined microorganisms according to the present invention. It is a vector containing one or more compartments of a gene or coding sequence of the invention, where appropriate one or more amino acid deletions, additions or substitutions can be introduced to modify the sequence of the invention, for example to functionally break it. Involves the production of (knockout vectors). The introduced sequence may for example also be a homologue from the microorganism of interest or may be derived from a mammal, yeast or insect source. Vectors used for homologous recombination may be modified in such a way that the endogenous gene is mutated or vice versa modified during homologous recombination but still encodes a functional protein (e.g., an upstream regulatory region modifies the expression of the endogenous protein). Can be modified). The modified compartment of the ME gene is in a homologous recombinant vector. Preparation of suitable vectors for homologous recombination are described, for example, in Thomas, K.R.and Capecchi, M.R. (1987) Cell 51: 503.
[148] Suitable host organisms are in principle all organisms which can express the nucleic acids of the invention, allelic variants thereof, functional equivalents or derivatives thereof. By host organism is meant eg bacterial, fungal, yeast, plant or animal cell. Preferred organisms are from bacteria such as organisms of the genus Escherichia such as Escherichia coli, Streptomyces, Bacillus or Pseudomonas, eukaryotic microorganisms such as Saccharomyces cerevisiae, Aspergillus, animals or plants Higher eukaryotic cells, for example Sf9 or CHO cells. Preferred organisms are of the genus Ashvian, in particular A. Selected from the Gossipy line.
[149] Successfully transformed organisms can likewise be selected via indicator genes present in a vector or expression cassette. An example of such an indicator gene is a gene for an enzyme that catalyzes anti-biotic and color tone-forming reactions that stain transformed cells. These may then be screened by automated cell sorting. Microorganisms that have been successfully transformed with the vector and have the appropriate antibiotic (eg, G418 or hygromycin) resistance genes can be selected with an appropriate antibiotic-containing medium or nutrient medium. Labeled proteins present on the cell surface can be used for selection by affinity chromatography.
[150] Combinations of host organisms and vectors suitable for the organism, such as plasmids, viruses or phages such as plasmids, phage lambda or μ or other suitable phage or transposons and / or other advantageous regulatory sequences with an RNA polymerase / promoter system, may be used to express the expression system. Form. The term "expression system" refers to a combination of, for example, mammalian cells, such as CHO cells, and vectors suitable for mammalian cells, such as pcDNA3neo vectors.
[151] If desired, the gene product may also be expressed in a transgenic organism such as a transgenic animal such as in particular a mouse, sheep or transgenic plant.
[152] Recombinant Production of Polypeptides:
[153] The present invention also relates to a method for recombinant production of a polypeptide of the invention or a functional, biologically active fragment thereof, of culturing a polypeptide-producing microorganism, inducing expression of the polypeptide in an appropriate place, and isolating it in a culture. Polypeptides may also be produced on an industrial scale in this manner if desired.
[154] Recombinant microorganisms can be cultured and fermented by known methods. Bacteria are for example 20-40 in TB or LB medium It can be grown at a temperature of ℃ and pH 6-9. Details of suitable culture conditions are described, for example, in T. Maniatis, E. F. Fritsch and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982).
[155] If the polypeptide is not secreted into the culture medium, the cells are then disrupted and the product is obtained from the lysate by known protein isolation methods. Alternatively, the cells can be disrupted by high frequency ultrasound, high pressure such as French pressure cells, osmolysis, detergent action, lytic enzymes or organic solvents, homogenizers or a combination of many of the methods mentioned.
[156] Polypeptides can be prepared by known chromatography methods such as molecular sieve chromatography (gel filtration) such as Q-Sepharose chromatography, ion exchange chromatography and hydrophobic chromatography, and other conventional methods such as ultrafiltration, crystallization, It can be purified by salting, dialysis and natural gel electrophoresis. Suitable methods are described, for example, in Cooper, T.G., Biochemische Arbeitsmethoden, Verlag Walter de Gruyter, Berlin, New York or Scopes, R., Protein Purification, Springer Verlag, New York, Heidelberg, Berlin.
[157] Particularly advantageous is the use of oligonucleotides that extend cDNA with vector systems or specific nucleotide sequences, and thus isolate recombinant proteins encoding modified polypeptides or fusion proteins, eg provided for simple purification. Suitable modifications of this type are modifications known as epitopes that can be recognized as antigens by, for example, so-called tags, such as 6-histidine anchors, or antibodies that act as anchors (see, eg, Harlow, E. and Lane, D., 1988, Antibodies: A Laboratory Manual.Cold Spring Harbor (NY) Press). These anchors can be used to attach the protein to a polymer matrix that can be packaged into a solid support, such as a chromatography column, or can be used on microtiter plates or another support.
[158] These anchors can be used simultaneously for the recognition of proteins as well. Conventional indicators such as fluorescent dyes, enzyme markers that form detectable reaction products after reaction with a substrate, or radiolabels alone or in combination with protein derivation anchors may be used to recognize proteins.
[159] The invention further relates to a method for microbiological production of vitamin B2 and / or its precursors and / or derivatives.
[160] When the conversion is carried out with recombinant microorganisms, for example about 20 in the complex medium, preferably in the presence of oxygen The microorganisms are initially incubated at a culture temperature of < RTI ID = 0.0 > C < / RTI > In order to be able to better control the reaction, it is preferred to use an inducible promoter. The culture is continued for 12 hours to 3 days in the presence of oxygen after induction of vitamin B2 production.
[161] The following non-limiting examples illustrate certain embodiments of the present invention.
[162] Detailed description of the general experiment
[163] a) general cloning method
[164] Cloning steps performed for the purposes of the present invention such as restriction cleavage, agarose gel electrophoresis, purification of DNA fragments, transfer of nucleic acids to nitrocellulose and nylon membranes, ligation of DNA fragments, E. Transformation of E. coli cells, bacterial cultures, replication of phage and sequencing of recombinant DNA were performed as described in Sambrook et al. (1989) cited in part.
[165] b) polymerase chain reaction (PCR)
[166] PCR was performed according to standard protocols using the following standard mixtures:
[167] 8 μl of dNTP mix (200 μM), 10 μl of Taq polymerase buffer without MgCl ₂ (10 ×), 8 μl of MgCl ₂ (25 mM), 1 μl each of primer (0.1 μM), 1 μl of DNA to be amplified, Taq polymerization Add 2.5 U of enzyme (MBI Fermentas, Vilnius, Lithuania), demineralized water to 100 μl.
[168] c) this. Cultivation of E. coli
[169] Recombinant tooth. E. coli DH5α system was added to LB-amp medium (Tryptone 10.0 g, NaCl 5.0 g, yeast extract 5.0 g, ampicillin 100 g / ml, H₂0 to 1000 ml) Incubated at ℃. For this purpose, one colony in each case was transferred from the agar plate into 5 ml of LB-amp using an inoculation loop. After incubation with shaking at 220 rpm for about 18 hours, 400 ml of medium in a 2 L flask was inoculated into 4 ml of culture. 42 after the value of OD578 reaches 0.8 to 1.0 Heat-shock induction for 3-4 hours at < RTI ID = 0.0 > P450 expression in E. coli was induced.
[170] d) Purification of the desired product from the culture
[171] The desired product can be isolated from microorganisms or culture supernatants by various methods known in the art. If the desired product is not secreted by the cells, the cells can be harvested from the culture by slow centrifugation and the cells can be lysed by standard techniques such as mechanical force or sonication.
[172] Cell debris was removed by centrifugation and a supernatant fraction containing soluble protein was obtained for further purification of the desired compound. If the product is secreted by the cells, the cells are removed from the culture by low speed centrifugation and the supernatant fractions are retained for further purification.
[173] The supernatant fractions from the two purification methods were chromatographed using a suitable resin with the desired molecule retained on the chromatography resin, or passed later with higher selectivity than impurities. These chromatography steps can be repeated using the same or different chromatography resins as necessary. The skilled person is skilled in the selection of suitable chromatographic resins and their most effective use for the particular molecule to be purified. The purified product was concentrated by filtration or ultrafiltration and stored at a temperature where the stability of the product was the highest.
[174] Many purification methods are known in the art. These purification techniques are described, for example, in Bailey, J.E. & Ollis, D. F. Biochemical Engineering Fundamentals, McGraw-Hill: New York (1986).
[175] Identification and purity of the isolated compounds can be determined by the prior art. These include high performance liquid chromatography (HPLC), spectroscopic methods, staining methods, thin layer chromatography, NIRS, enzymatic analysis or microbiological analysis. These analytical methods are described in Patek et al. (1994) Appl. Environ.Microbiol. 60: 133-140; Malakhova et al. (1996) Biotekhnologiya 11 27-32; and Schmidt et al. (1998) Bioprocess Engineer. 19: 67-70.Ullmann's Encyclopedia of Industrial Chemistry (1996) Vol.A27, VCH: Weinheim, pp. 89-90, pp. 521-540, pp. 540-547, pp. 559-566, pp. 575- 581 and pp. 581-587; Michal, G (1999) Biochemical Pathways: An Atlasof Biochemistry and Molecular Biology, John Wiley and Sons; Fallon, A. et al. (1987) Applications of HPLC in Biochemistry in: Laboratory Techniques in Biochemistry and Molecular Biology, Vol. 17).
[176] e) General description of MPSS method, clone identification and homology investigation
[177] MPSS technology (.. The literature (Brenner et al, Nat Biotechnol ( 2000) 18, the Massive parallel signature sequencing Nature Singh (M assive P arallel S ignature equencing S) described in the 630-634); also incorporated by reference thereto) an event It was applied to the production of vitamin B2- fungi Ashdod via Ghosh blood. With the help of this technology, very accurate quantitative information on the expression levels of many genes in eukaryotes can be obtained. It includes mRNA of an organism that is isolated at a certain time X, transcribed into cDNA with the help of a reverse transcriptase, and then cloned into a specific vector with a specific tag sequence. Cloning into the vector through the tag sequence of the vector yielded a very sufficient (about 1000-fold or more) number of vectors with statistically different tag sequences for each unique DNA molecule.
[178] The vector insert was then cut with the tag. DNA molecules obtained in this manner were then incubated with microbeads with the molecular counterparts of the tags mentioned. It can be assumed that after incubation each microbead was loaded through a specific tag or counterpart with only one type of DNA molecule. The beads could be moved into a specific flow cell and fixed to mass sequencing all the beads with the aid of a sequencing and digital color camera adapted based on the fluorescent dye. Numerical height analysis is possible with this method, but was limited by the read width of about 16 to 20 base pairs. However, this sequence length was sufficient to make a clear correlation between sequences and genes possible for most organisms (20 bp has a sequence frequency of ˜1 × 10 ¹² , whereas the human genome is “only” ˜3 × 10). ⁹ bp).
[179] The data obtained in this way were analyzed by counting the number of identical sequences and comparing the frequencies of each other. Frequently generated sequences show high levels of expression, and sequences that occur alone show low levels of expression. When mRNA is isolated at two different time zones (X and Y), chronological expression patterns of individual genes can be created.
[180] Example 1:
[181] MRNA Isolation from Ashbia Ghoshpi
[182] Ashvia Gossip was cultured in a manner known per se (nutritional medium: 27.5 g / l yeast extract; 0.5 g / l magnesium sulfate; 50 ml / l soybean oil; pH 7). Ashvia Goshpi mycelium samples were taken at various times during fermentation (24, 48 and 72 hours) and the corresponding RNA or mRNA was isolated therefrom according to the protocol of Sambrook et al. (1989).
[183] Example 2:
[184] Use of MPSS
[185] a. The mRNA isolated from the Ghosh blood is then carried out the above-described MPSS analysis.
[186] The data sets found were statistically analyzed and classified according to the significance of the difference in expression. This entails investigating both increasing and decreasing expression levels. Expression changes were divided into a) simple changes, b) changes after 24 hours, and c) changes after 48 hours.
[187] A 20 bp sequence showing expression change and found by MPSS analysis was then used as a probe and had an average insert size of about 1 kb.Ashbia GhoshpiHybridized with gene library from. In this case the hybridization temperature is about 30 to 57 It was the range of ° C.
[188] Example 3:
[189] Preparation of Genomic Genetic Libraries from Ashvia Goshpie
[190] Chromosomal DNA was initially isolated by the method of Bright and Philippsen, Gene (1991) 109: 99-105 and Mohr, 1995, PhD Thesis, Biozentrum Universitaet Basel, Switzerland to prepare a genomic DNA library.
[191] DNA was partially cut with Sau3A. For this purpose, 6 μg of genomic DNA was Sau3A digested with varying amounts of enzyme (0.1-1 U). Fragments were fractionated with sucrose density gradient. 1 kb region was isolated and QiaEx extracted. The largest fragment was ligated to the BamHI-cleaving vector pRS416 (Sikorski and Hieter, Genetics (1988) 122; 19-27) (90 ng of dephosphorylated vector BamHI-cleavage; 198 ng of insert DNA; 5 ml of water; 10 2 μl of ligation buffer; 1 U ligase). Using this ligation mixture . E. coli laboratory strain XL-1 blue was transformed and the resulting clones were used to identify inserts.
[192] Example 4:
[193] Preparation of Directed Gene Library (CHIP Technology)
[194] About 25,000 colonies of the Ashvia Gossipi gene library (which correspond to about three-fold coverage of the genome) were transferred in the manner directed to the nylon membrane, followed by colonies as described in Sambrook et al. (1989). The hybridization method was used. Oligonucleotides were synthesized from 20 bp sequences identified by MPSS analysis and radiolabeled at ³² P. Ten labeled oligonucleotides with the same melting point in each case were combined and hybridized with the nylon membrane. After hybridization and washing steps positive clones were identified by radiograph and analyzed directly by PCR sequencing.
[195] In this way, it has an insert with the internal designation "up to 8", S. From Cerevisiae, clones with significant homology with the MIPS tag "Cwp1" were identified. The insert had the nucleic acid sequence shown in SEQ ID NO: 1.
[196] In this way, it has an insert with the internal designation "up 25/39", S. Levy cyano three clones having the additional MIPS tag "ARK1" with significant homology were identified from the. The insert had the nucleic acid sequence shown in SEQ ID NO: 8.
[197] In this way, it has an insert with the internal designation "Raising 46", S. From the three Levy cyano and identified a clone having the additional MIPS tag "BUD2 / CLA2" with significant homology. The insert had the nucleic acid sequence shown in SEQ ID NO: 12.
[198] In this way, it has an insert with the internal designation "raising 103", s . Levy cyano three clones having the additional MIPS tag "Aor1" with significant homology were identified from the. The insert had the nucleic acid sequence shown in SEQ ID NO: 17.
[199] In this way, it has an insert with the internal name "Up and 128", S. Levy cyano three clones having the additional MIPS tag "Ykl179c" with significant homology were identified from the. The insert had the nucleic acid sequence shown in SEQ ID NO: 21.
[200] In this way, it has an insert with the internal designation "up 150", S. Levy cyano three clones having the additional MIPS tag "Scp1" with significant homology were identified from the. The insert had the nucleic acid sequence shown in SEQ ID NO: 26.
[201] In this way, Mr. C. has an insert with the internal name "Up and 177" . From the end of earth and sand it was identified a clone having the additional MIPS tag "EPD1" with significant homology. The insert had the nucleic acid sequence shown in SEQ ID NO: 30.
[202] In this way, it has an insert with the internal designation "Up and 145", S. Levy cyano three clones having the additional MIPS tag "Aip2" with significant homology were identified from the. The insert had the nucleic acid sequence shown in SEQ ID NO: 36.
[203] Example 5:
[204] Analysis of Sequence Data by BLASTX Survey
[205] Analysis of the resulting nucleic acid sequences, ie, BLASTX investigation of the sequence database, assigned their function to functional amino acid sequences. Almost all of the amino acid sequence homology was found to relate to the process three Levy MY cyano as Saccharomyces (baker's yeast). Since this organism has already been fully sequenced, more detailed information about these genes is available at http://www.mips.gsf.de/proj/yeast/search/code_search.htm. See also.
[206] Thus, S. To the amino acid fragment of the Celebi from Asia it revealed homology. Corresponding alignments are shown in the accompanying FIGS. 1 and 8.
[207] a) the amino acid sequence derived from the coding strand in SEQ ID NO: 1 is S. Serevisiae had significant sequence homology with the cell-wall precursor protein. s. The derived amino acid sequence from which a part-Levy cyano three parts of the protein to the sequence (corresponding to nucleotides 595 to 1092 from SEQ ID NO: 1) is shown in FIG. SEQ ID NO: 2 and SEQ ID NO: 3 show in each case an N-terminal extended amino acid sub-sequence.
[208] Thus, revealed a . Gossipy nucleic acid sequences could direct the function of the cell-wall precursor protein.
[209] b) the amino acid sequence derived from the complementarity strand corresponding to SEQ ID NO: 8 . Of from three to Levy cyano serine-threonine kinase and had the significant sequence homology. s. The amino acid sub-sequences (corresponding to nucleotides 1067 to 84 from SEQ ID NO: 8) derived from the sub-sequences of the protein in Serevisia are shown in FIG. 2. SEQ ID NO: 9 shows the N-terminal extended amino acid partial-sequence.
[210] Thus, revealed a . Gossipy nucleic acid sequences could direct the function of serine-threonine kinases.
[211] c) the amino acid sequence derived from the complementarity strand for SEQ ID NO: 12 is S. It had a GTPase- activating protein and significant sequence homology to three from Levy cyano. s. The amino acid partial-sequences (corresponding to nucleotides 475 to 353 from SEQ ID NO: 12) derived from the sub-sequences of the protein in cerevisiae are shown in FIG. 3A. s. A sequence of additional amino acids derived therefrom portion-Levy cyano three parts of the protein to the sequence (corresponding to nucleotides 1 to 351 from SEQ ID NO: 12) is shown in Figure 3B. SEQ ID NO: 13 and SEQ ID NO: 14 each represented an N-terminal extended amino acid partial-sequence.
[212] Thus, revealed a . Gosh Avoid nucleic acid sequences could be assigned the function of activated protein GTPase-.
[213] d) the amino acid sequence derived from the complementary strand corresponding to SEQ ID NO: 17 is associated with 5r resistance to actin overexpression . It had a protein with significant sequence homology to three from Levy cyano. s. The amino acid partial-sequences (corresponding to nucleotides 933 to 157 from SEQ ID NO: 17) derived from the sub-sequences of the enzyme in cerevisiae are shown in FIG. 4. SEQ ID NO: 18 shows an N-terminal extended amino acid partial-sequence.
[214] Thus, revealed a . Gossipy nucleic acid sequences could direct the function of proteins with actin overexpression resistance.
[215] e) the amino acid sequence derived from the coding strand for SEQ ID NO: 21 is S. a. Nuf1p- had a similar protein with significant sequence homology of from three to Levy cyano. s. The amino acid partial-sequence derived from the sub-sequence of the enzyme in cerevisiae (corresponding to the complementarity strand for nucleotides 117-794 from SEQ ID NO: 21) is shown in FIG. SEQ ID NO: 22 shows the N-terminal extended amino acid partial-sequence.
[216] Thus, revealed a . Gosh Avoid nucleic acid sequences could be assigned the function of similar proteins Nuf1p-.
[217] f) an amino acid sequence derived from the coding strand in SEQ ID NO: 26 S. Carl ponin from the Celebi Asia - had a homogeneous protein with significant sequence homology. The amino acid sub-sequences derived therefrom (corresponding to nucleotides 438 to 767 from SEQ ID NO: 26) are shown in FIG. 6. SEQ ID NO: 27 shows an N-terminal extended amino acid partial-sequence.
[218] Thus, revealed a . Gossipy nucleic acid sequences could direct the function of calponin-homologous proteins.
[219] g) the amino acid sequence derived from the complementarity strand corresponding to SEQ ID NO: 30 is represented by C. a . Seeds are required for mycelium occurs at the end of Tosa above. It had a protein with significant sequence homology from the end of earth and sand. Seed. The amino acid sub-sequences derived from the sub-sequences of the maltosa protein (corresponding to nucleotides 983-651 from SEQ ID NO: 30) are shown in FIG. 7A. Seed. Another amino acid sub-sequence derived from the sub-sequence of the maltosa protein (corresponding to nucleotides 661 to 596 from SEQ ID NO: 30) is shown in FIG. 7B. Seed. A third amino acid sub-sequence derived from the sub-sequence of the maltosa protein (corresponding to nucleotides 591 to 1 from SEQ ID NO: 30) is shown in FIG. 7C. SEQ ID NO: 31, SEQ ID NO: 32 and SEQ ID NO: 33 in each case indicated an N-terminal extended amino acid partial-sequence.
[220] Thus, revealed a . Mr. Ghosh blood nucleic acid sequence. In maltosa , it was possible to specify the function of proteins essential for the development of gastric mycelia.
[221] h) The amino acid sequence derived from the coding strand in SEQ ID NO: 36 has an S. aureus interaction with actin . It had a protein with significant sequence homology to three from Levy cyano. s. The amino acid partial-sequences (corresponding to nucleotides 2 to 148 from SEQ ID NO: 36) derived from the sub-sequences of the enzyme in cerevisiae are shown in FIG. 8. SEQ ID NO: 37 shows the N-terminal extended amino acid partial-sequence.
[222] Thus, revealed a . Gossipy nucleic acid sequences could direct the function of proteins that interact with actin.
[223] Example 6:
[224] Isolation of Full-length DNA
[225] a) a . Preparation of Gossipy Gene Library
[226] a. Prepared from a 100 ml culture medium for two days growth from - (inositol 0.3 g was added also to the 1000 ml glucose 10 g, peptone 10 g, yeast extract 1 g, Maio) a high molecular weight cellular complete DNA from Ghosh blood liquid MA2 medium It was. The mycelium is filtered off, washed twice with distilled H ₂ O, suspended in 10 ml of 1 M sorbitol, 20 mM EDTA, containing 20 mg of 20T of zimolyse, gently shaken and 30 to 60 at 27 ° C. Incubate for minutes. Protoplast suspensions were adjusted with 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 100 mM EDTA and concentration 0.5% sodium dodecyl sulfate (SDS) and incubated at 65 ° C. for 20 minutes. After twice extraction with phenol / chloroform (1: 1 (volume / volume)), the DNA was precipitated with isopropanol, suspended in TE buffer, treated with RNase, reprecipitated with isopropanol and resuspended in TE. .
[227] Genomic DNA selected according to size and partially digested with Sau3 A was bound to the dephosphorylated arm of the cosmid vector Super-Cos1 (Stratagene) . A Gospy Cosmid Gene Library was prepared. The Super-Cos1 vector was cleaved with X bal to open between the two cos sites, dephosphorylated with calf enteric alkaline phosphatase (Boehringer) and then the cloning site with Bam HI. 2.5 μg of partially truncated chromosomal DNA, 1 μg of Super-Cos1 vector arm, 40 mM Tris-HCl, pH 7.5, 10 mM MgCl ₂ , 1 mM dithiothreitol, 0.5 mM ATP and 2 Weiss units T4- Ligation was performed overnight at 15 ° C. in 20 μl containing DNA ligase (Boehringer). Ligation products were packaged in vitro using the extract and Stratagen's protocol (Gigapack II Packaging Extract). This using a packaged material . E. coli NM554 ( recA13, araD139, (ara, leu) 7696, (lac) 17A, galU, galK, hsrR, rps (str ^r ), mcrA, mcrB ) were infected and distributed on LB plates containing ampicillin (50 μg / ml). A. with an average length of 30 to 45 kb . Transformants containing a Gospy insert were obtained.
[228] b) storage and screening of cosmid gene libraries
[229] Overall, 4 x 10 ⁴ new single colonies alone were frozen medium (36 mMK ₂ HPO ₄ /13.2 mM KH ₂ PO ₄ , 1.7 mM sodium citrate, 0.4 mM MgSO ₄ , 6.8 mM (NH ₄ ) ₂ SO ₄ , 4.4 Inoculate wells of 96-well microtiter plates (Falcon No. 3072) in 100 μl of LB medium fed% (w / v) glycerol) and ampicillin (50 μg / ml) and shake at 37 ° C. with shaking. Grown overnight and frozen at -70 ° C. This plate was thawed briefly and then copied to fresh medium using a 96-well replicator sterilized in an ethanol bath by subsequent evaporation of ethanol on a hot plate. Plates were briefly shaken in microtiter shakers (Infors) before freezing and after thawing (before other measurements) to ensure homogenous cells. Single clones are placed on nylon membranes using a robotic system (Bio-Robotics) (GeneScreen Plus , New England Nuclear) that can transfer small amounts of liquid to the nylon membrane from 96 wells of the microtiter plate. I was. After culturing (1920 clones) from 96-well microtiter plates, membranes were placed on the surface of LB agar with ampicillin (50 μg / ml) in a 22 × 22 cm culture dish (Nunc), Incubate overnight at 37 ° C. Before reaching the cell confluence, the membrane was blocked including a five minute exposure of the filter to steam on a pad impregnated with a denaturing solution on a boiling water bath as a further treatment after the first denaturation step (Herrmann, BG, Barlow, DP and Lehrach, H). (1987), Cell 48, pp. 813-825).
[230] Inhalation of [alpha- ³² P] dCTP with high specific activity using the random hexamer primer method (Feinberg, AP and Vogelstein, B. (1983), Anal. Biochem. 132, pp. 6-13) Labeled with double-stranded probe. The membrane was prehybridized and 50% (volume / volume) formamide, 600 mM sodium phosphate, pH 7.2, 1 mM EDTA, 10% dextran sulfate, 1% SDS, and ³² P-labeled probes at 42 ° C. Hybridization for 6-12 hours in 10 × Denhardt solution containing salmon sperm DNA (50 μg / ml) with −1 × 10 ⁶ cpm / ml). Typically, the washing step is carried out at 55-65 ° C. for about 1 hour in 13-30 mM NaCl, 1.5-3 mM sodium citrate, pH 6.3, 0.1% SDS, and the filter is Kodak enriched at −70 ° C. Radiomagnetography was performed on the screen for 12 to 24 hours. Individual membranes were successfully reused more than 20 times for counting. The filter was incubated at 95 ° C. in 2 mM Tris-HCl, pH 8.0, 0.2 mM EDTA, 0.1% SDS for 2 × 20 minutes to strip between the radiographs.
[231] c) recovery of positive colonies from stored gene libraries
[232] Frozen bacterial cultures in microtiter wells were scraped using sterile disposable lancets and the material was lined onto LB agar Petri dishes containing ampicillin (50 μg / ml). DNA was produced by alkaline lysis method (Birnboim, H. C. and Doly, J. (1979), Nucleic Acids Res. 7, pp. 1513-1523) by inoculating liquid cultures with single colonies subsequently.
[233] d) full-length DNA
[234] As described above, it was possible to identify clones with inserts with appropriate complete sequences. These clones have the following internal names:
[235] "Up 8v". The insert comprising the complete sequence had the nucleic acid sequence shown in SEQ ID NO: 4. The protein encoded thereby comprises preferably one or more amino acid sequences shown in SEQ ID NOs: 5, 6 and 7.
[236] "Upload 25 / 39v". The insert comprising the complete sequence had the nucleic acid sequence shown in SEQ ID NO: 10.
[237] "Up 46v". The insert comprising the complete sequence had the nucleic acid sequence shown in SEQ ID NO: 15.
[238] "Raise 103v". The insert comprising the complete sequence had the nucleic acid sequence shown in SEQ ID NO: 19.
[239] "Up to 128v". The insert comprising the complete sequence had the nucleic acid sequence shown in SEQ ID NO: 23. The protein encoded thereby preferably comprises one or more amino acid sequences shown in SEQ ID NOs: 24 and 25.
[240] "Up 150v". The insert comprising the complete sequence had the nucleic acid sequence shown in SEQ ID NO: 28.
[241] "Upload 177v". The insert comprising the complete sequence had the nucleic acid sequence shown in SEQ ID NO: 34.
[242] "Upload 145v". The insert comprising the complete sequence had the nucleic acid sequence shown in SEQ ID NO: 38.
[243] Sequence overview Sequence numberRaiseDescription of the sequenceSequence homology One008DNA part-sequences. Cell Wall Precursor Protein Cwp1 from Serevisiae 2008Amino acid sub-sequences derived from the complementary strand to SEQ ID NO: 1 3008Amino acid sub-sequences derived from the complementary strand to SEQ ID NO: 1 4008DNA full-length sequence 5008Amino acid sequence corresponding to coding region of SEQ ID NO: 4 in positions 523 to 996 6008Amino acid sequence corresponding to coding region of SEQ ID NO: 4 of positions 1523 to 2035 7008Amino acid sequence corresponding to coding region of SEQ ID NO: 4 in positions 2222 to 2425 8025/039DNA part-sequences. Serine-Threonine Protein Kinase from Serevisiae 9025/039Amino acid partial-sequence derived from the complementary strand to SEQ ID NO: 8 10025/039DNA full-length sequence 11025/039Amino acid sequence corresponding to coding region of SEQ ID NO: 10 of positions 821 to 3703 12046DNA part-sequences. GTPase-Activated Protein from Serevisiae 13046Amino acid sub-sequences derived from the complementary strand to SEQ ID NO: 12 14046Amino acid sub-sequences derived from the complementary strand to SEQ ID NO: 12 15046DNA full-length sequence 16046Amino acid sequence corresponding to coding region of SEQ ID NO: 15 of positions 314 to 3556
[244] Sequence numberRaiseDescription of the sequenceSequence homology 17103DNA part-sequences. Proteins that have or contribute to actin overexpression resistance from cerevisiae 18103Amino acid partial-sequence derived from the complementary strand to SEQ ID NO: 17 19103DNA full-length sequence 20103Amino acid sequence corresponding to coding region of SEQ ID NOs: 19 from positions 584 to 1441 21128DNA part-sequences. Nuf1p-like protein from Serevisiae 22128Amino acid sub-sequences derived from the coding strand for SEQ ID NO: 21 23128DNA full-length sequence 24128Amino acid sequence corresponding to coding region of SEQ ID NO: 23 in positions 272 to 703 25128Amino acid sequence corresponding to coding region of SEQ ID NO: 23 at positions 775 to 1374 26150DNA part-sequences. Calponin-homologous protein from cerevisiae 27150Amino acid sub-sequences derived from the coding strand for SEQ ID NO: 26 28150DNA full-length sequence 29150Amino acid sequence corresponding to coding region of SEQ ID NO: 28 of positions 628 to 1227
[245] Sequence numberRaiseDescription of the sequenceSequence homology 30177DNA part-sequenceEssential Proteins for Gastric Mycelial Development in Candida Maltosa 31177Amino acid partial-sequence derived from the complementary strand to SEQ ID NO: 30 32177Amino acid partial-sequence derived from the complementary strand to SEQ ID NO: 30 33177Amino acid partial-sequence derived from the complementary strand to SEQ ID NO: 30 34177DNA full-length sequence 35177Amino acid sequence corresponding to coding region of SEQ ID NO: 34 at positions 768 to 2366 36145DNA part-sequenceS interacting with actin. Protein from cerevisiae 37145Amino acid sub-sequences derived from the coding strand for SEQ ID NO: 36 38145DNA full-length sequence 39145Amino acid sequence corresponding to coding region of SEQ ID NO: 38 at positions 735 through 2366

权利要求:
Claims (24)
[1" claim-type="Currently amended] Polynucleotides that can be isolated from Ashvia Gospy and encode proteins associated with the construction of cell walls and / or cytoskeleton.
[2" claim-type="Currently amended] The polynucleotide of claim 1 which is related to the construction of the cell wall and / or cytoskeleton and has the structural and / or functional properties shown in Table 1.
[3" claim-type="Currently amended] A nucleic acid sequence as set forth in claim 1 or 2, preferably as set forth in SEQ ID NO: 1, 8, 12, 17, 21, 26, 30 or 36, which can be isolated from Ashvia Gospy ; Polynucleotides complementary thereto; And a polynucleotide comprising a sequence derived from these polynucleotides through degeneracy of the genetic code.
[4" claim-type="Currently amended] The polynucleotide of claim 3 comprising the nucleic acid sequence set forth in SEQ ID NO: 4, 10, 15, 19, 23, 28, 34 or 38 or fragments thereof.
[5" claim-type="Currently amended] Oligonucleotides which hybridize with the polynucleotide according to any one of claims 1 to 4 under particularly stringent conditions.
[6" claim-type="Currently amended] Polynucleotides which hybridize with the oligonucleotides according to claim 5 under particularly stringent conditions and which encode a gene product from a microorganism of the genus Ashvian or a functional equivalent of this gene product.
[7" claim-type="Currently amended] A polynucleotide comprising a nucleic acid sequence according to any one of claims 1 to 4 or a fragment thereof or a polynucleotide according to claim 6; Or SEQ ID NO: 2, 3, 5, 6, 7, 9, 11, 13, 14, 16, 18, 20, 22, 24, 25, 27, 29, 31, 32, 33, 35, 37 or SEQ ID NO 39 A polypeptide having an amino acid sequence comprising at least 10 consecutive amino acid residues shown in; And functional equivalents thereof, in particular functional equivalents having the properties defined in claim 2.
[8" claim-type="Currently amended] An expression cassette comprising a nucleic acid sequence according to any one of claims 1 to 6 operably linked to one or more regulatory nucleic acid sequences.
[9" claim-type="Currently amended] Recombinant vector comprising at least one expression cassette according to claim 8.
[10" claim-type="Currently amended] Prokaryotic or eukaryotic host transformed with one or more vectors according to claim 9.
[11" claim-type="Currently amended] Modulating the functional expression of one or more genes encoding a polypeptide according to claim 7; Or a prokaryotic or eukaryotic host which reduces or increases the biological activity of the polypeptide according to claim 7.
[12" claim-type="Currently amended] The host according to claim 10 or 11, which is derived from the Ashvian genus.
[13" claim-type="Currently amended] 13. An expression cassette according to claim 8, a vector according to claim 9, or a host according to claim 10, for microbiologically producing vitamin B 2 and / or precursors and / or derivatives thereof. Use of
[14" claim-type="Currently amended] Use of an expression cassette according to claim 8, a vector according to claim 9, or a host according to claim 10 for recombinantly producing a polypeptide according to claim 7.
[15" claim-type="Currently amended] A microorganism capable of microbiologically producing vitamin B2 and / or its precursors and / or derivatives thereof is treated with an effector which interacts with, in particular binds to, a target selected from the polypeptide according to claim 7 or the nucleic acid sequence encoding the same. Identifying the effect of the effector on the microbiological production of vitamin B2 and / or its precursors and / or derivatives; A method of detecting effector targets for modulating the microbiological production of vitamin B2 and / or precursors and / or derivatives thereof, wherein the targets are optionally isolated.
[16" claim-type="Currently amended] A microorganism capable of microbiologically producing vitamin B2 and / or its precursors and / or derivatives thereof is treated with an effector that interacts with a target selected from a polypeptide according to claim 7 or a nucleic acid sequence encoding it and (Or) a method of modulating microbiological production of precursors and / or derivatives thereof.
[17" claim-type="Currently amended] a) an antibody or antigen-binding fragment thereof;
b) a polypeptide ligand different from a) and interacting with the polypeptide according to claim 7;
c) low molecular weight effectors modulating the biological activity of the polypeptide according to claim 7;
d) antisense nucleic acid sequences
An effector for a target selected from a polypeptide according to claim 7 or a nucleic acid sequence encoding the same.
[18" claim-type="Currently amended] A host according to any one of claims 10 to 12 is cultured under conditions favorable for the production of vitamin B2 and / or precursors and / or derivatives thereof, and the desired product (s) is isolated from the culture mixture, Method for microbiological production of vitamin B2 and / or precursors and / or derivatives thereof.
[19" claim-type="Currently amended] The method of claim 18, wherein the host is treated with the effector according to claim 17 before and / or during its culture.
[20" claim-type="Currently amended] 19. The method of claim 18 or claim 19, wherein the host is selected from doeneungeot Ashdod vias in the microorganism.
[21" claim-type="Currently amended] 21. The method of any one of claims 18-20, wherein the microorganism is a host according to any one of claims 10-12.
[22" claim-type="Currently amended] The polynucleotide according to any one of claims 1 to 4 and 6 as a target for modulating the production of vitamin B2 and / or its precursors and / or derivatives in the microorganisms of the genus Ashbia Use of Polypeptides.
[23" claim-type="Currently amended] Claims 1 to 4 and as targets for regulating the construction of cell walls and / or cytoskeleton in microorganisms of the genus Ashvia during cultivation for microbiological production of vitamin B2 and / or precursors and / or derivatives thereof. Use of a polynucleotide according to claim 6 or a polypeptide according to claim 7.
[24" claim-type="Currently amended] The host of claim 12 having modified cell walls and / or cytoskeletal structures.

类似技术:

---

公开号 | 公开日 | 专利标题

---

Clark et al.1993|Selective amplification of additional members of the ADP-ribosylation factor | family: cloning of additional human and Drosophila ARF-like genes

---

Kimura et al.2001|Peroxisomal metabolic function is required for appressorium-mediated plant infection by Colletotrichum lagenarium

---

KR100878334B1|2009-01-14|Corynebacterium Glutamicum Genes Encoding Metabolic Pathway Proteins

---

Kendall et al.1990|Trypanosoma cruzi glycosomal glyceraldehyde‐3‐phosphate dehydrogenase does not conform to the ‘hotspot’topogenic signal model.

---

Gressler et al.2011|Multifactorial induction of an orphan PKS-NRPS gene cluster in Aspergillus terreus

---

Lanahan et al.1992|Growth factor-induced delayed early response genes.

---

AU735082B2|2001-06-28|Isolation and identification of novel polymerases

---

Choi et al.1997|The adenylate cyclase gene MAC1 of Magnaporthe grisea controls appressorium formation and other aspects of growth and development.

---

US6525190B1|2003-02-25|Amidase

---

EP1730291B1|2012-12-05|Nitrile hydratase of rhodococcus

---

KR101070110B1|2011-10-05|Aldehyde dehydrogenase gene

---

Schultz et al.2000|The classical arabinogalactan protein gene family of Arabidopsis

---

Pellier et al.2003|CLNR1, the AREA/NIT2‐like global nitrogen regulator of the plant fungal pathogen Colletotrichum lindemuthianum is required for the infection cycle

---

EP1066324B1|2009-08-26|Novel mammalian g-protein coupled receptors having extracellular leucine rich repeat regions

---

JP2008109942A|2008-05-15|Esterase

---

Lauter et al.1992|Developmental and light regulation of eas, the structural gene for the rodlet protein of Neurospora.

---

JP4257970B2|2009-04-30|Antifreeze protein produced by basidiomycetes

---

JP5357011B2|2013-12-04|Improved production of sphingoid bases using genetically engineered microbial strains

---

EP2183367B1|2019-05-22|Production of itaconic acid

---

Zhao et al.1993|Gene structure and expression of an unusual protein kinase from Plasmodium falciparum homologous at its carboxyl terminus with the EF hand calcium-binding proteins.

---

US20050019890A1|2005-01-27|Nitrilase homologs

---

Alberti-Segui et al.2001|Cytoplasmic dynein is required to oppose the force that moves nuclei towards the hyphal tip in the filamentous ascomycete Ashbya gossypii

---

Braun et al.1996|A stationary-phase gene in Saccharomyces cerevisiae is a member of a novel, highly conserved gene family.

---

US6071700A|2000-06-06|Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions

---

Heller et al.2012|The mitogen-activated protein kinase BcSak1 of Botrytis cinerea is required for pathogenic development and has broad regulatory functions beyond stress response

同族专利:

---

公开号 | 公开日

---

WO2003018626A2|2003-03-06|

---

CN1543475A|2004-11-03|

---

EP1421110A2|2004-05-26|

---

AU2002327839A1|2003-03-10|

---

JP2005522984A|2005-08-04|

---

US20050221460A1|2005-10-06|

---

WO2003018626A3|2003-12-24|

---

CA2456828A1|2003-03-06|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
2001-08-22|Priority to DE10141066.2

---

2001-08-22|Priority to DE10141063.8

---

2001-08-22|Priority to DE10141057

---

2001-08-22|Priority to DE10141065.4

---

2001-08-22|Priority to DE10141063

---

2001-08-22|Priority to DE10141058.1

---

2001-08-22|Priority to DE10141060

---

2001-08-22|Priority to DE10141061

---

2001-08-22|Priority to DE10141057.3

---

2001-08-22|Priority to DE10141064

---

2001-08-22|Priority to DE10141058

---

2001-08-22|Priority to DE10141064.6

---

2001-08-22|Priority to DE10141061.1

---

2001-08-22|Priority to DE10141065

---

2001-08-22|Priority to DE10141066

---

2001-08-22|Priority to DE10141060.3

---

2002-03-06|Priority to DE10209827.1

---

2002-03-06|Priority to DE10209827

---

2002-04-11|Priority to DE10216034

---

2002-04-11|Priority to DE10216034.1

---

2002-04-11|Priority to DE10216028

---

2002-04-11|Priority to DE10216028.7

---

2002-05-16|Priority to DE10221921

---

2002-05-16|Priority to DE10221918.4

---

2002-05-16|Priority to DE10221918

---

2002-05-16|Priority to DE10221919.2

---

2002-05-16|Priority to DE10221919

---

2002-05-16|Priority to DE10221906

---

2002-05-16|Priority to DE10221906.0

---

2002-05-16|Priority to DE10221921.4

---

2002-06-07|Priority to DE10225411.7

---

2002-06-07|Priority to DE10225411

---

2002-08-21|Application filed by 바스프 악티엔게젤샤프트

---

2002-08-21|Priority to PCT/EP2002/009355

---

2004-04-03|Publication of KR20040029000A

优先权:

---

申请号 | 申请日 | 专利标题

---

DE10141063.8|2001-08-22|

---

DE10141057|2001-08-22|

---

DE10141065.4|2001-08-22|

---

DE10141063|2001-08-22|

---

DE10141058.1|2001-08-22|

---

DE10141060|2001-08-22|

---

DE10141061|2001-08-22|

---

DE10141057.3|2001-08-22|

---

DE10141064|2001-08-22|

---

DE10141058|2001-08-22|

---

DE10141064.6|2001-08-22|

---

DE10141061.1|2001-08-22|

---

DE10141065|2001-08-22|

---

DE10141066|2001-08-22|

---

DE10141060.3|2001-08-22|

---

DE10141066.2|2001-08-22|

---

DE10209827|2002-03-06|

---

DE10209827.1|2002-03-06|

---

DE10216034.1|2002-04-11|

---

DE10216028|2002-04-11|

---

DE10216028.7|2002-04-11|

---

DE10216034|2002-04-11|

---

DE10221918.4|2002-05-16|

---

DE10221918|2002-05-16|

---

DE10221919.2|2002-05-16|

---

DE10221919|2002-05-16|

---

DE10221906|2002-05-16|

---

DE10221906.0|2002-05-16|

---

DE10221921.4|2002-05-16|

---

DE10221921|2002-05-16|

---

DE10225411|2002-06-07|

---

DE10225411.7|2002-06-07|

---

PCT/EP2002/009355|WO2003018626A2|2001-08-22|2002-08-21|Novel genetic products from ashbya gossypii, associated with the structure of the cell wall or the cytoskeleton|